CN109562093A - 含peitc的药物组合物及其在癌症治疗中的应用 - Google Patents

含peitc的药物组合物及其在癌症治疗中的应用 Download PDF

Info

Publication number
CN109562093A
CN109562093A CN201780037010.4A CN201780037010A CN109562093A CN 109562093 A CN109562093 A CN 109562093A CN 201780037010 A CN201780037010 A CN 201780037010A CN 109562093 A CN109562093 A CN 109562093A
Authority
CN
China
Prior art keywords
peitc
cell
mutant
cancer
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780037010.4A
Other languages
English (en)
Inventor
宗方隆
程景才
M·阿加沃尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Jesse Pharmaceutical Co ltd
Original Assignee
Wuxi Jesse Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Jesse Pharmaceutical Co ltd filed Critical Wuxi Jesse Pharmaceutical Co ltd
Publication of CN109562093A publication Critical patent/CN109562093A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

本发明提供了一种PEITC的用途，用于制备一制剂或组合物，所述制剂或组合物用于(a)改变突变型p53，使其恢复野生型活性，(b)抑制突变型p53所导致的肿瘤细胞增殖，(c)诱导突变型p53肿瘤细胞的凋亡，和/或(d)预防或治疗基于p53突变引起的疾病。本发明还提供了一种p53基因检测试剂的用途，包括PEITC和p53基因检测试剂的试剂盒以及体外非治疗性地抑制肿瘤细胞的方法。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201780037010.4A 2016-04-18 2017-04-18 含peitc的药物组合物及其在癌症治疗中的应用 Pending CN109562093A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2016102404598 2016-04-18
CN201610240459.8A CN107303291A (zh) 2016-04-18 2016-04-18 含peitc的药物组合物及其在癌症治疗中的应用
PCT/CN2017/080960 WO2017181943A1 (zh) 2016-04-18 2017-04-18 含peitc的药物组合物及其在癌症治疗中的应用

Publications (1)

Publication Number Publication Date
CN109562093A true CN109562093A (zh) 2019-04-02

Family

ID=60115607

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610240459.8A Pending CN107303291A (zh) 2016-04-18 2016-04-18 含peitc的药物组合物及其在癌症治疗中的应用
CN201780037010.4A Pending CN109562093A (zh) 2016-04-18 2017-04-18 含peitc的药物组合物及其在癌症治疗中的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610240459.8A Pending CN107303291A (zh) 2016-04-18 2016-04-18 含peitc的药物组合物及其在癌症治疗中的应用

Country Status (2)

Country Link
CN (2) CN107303291A (zh)
WO (1) WO2017181943A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220049274A1 (en) * 2018-09-12 2022-02-17 Institute For Basic Science Composition for inducing death of cells having mutated gene, and method for inducing death of cells having mutated gene by using composition
CN110241218A (zh) * 2019-07-11 2019-09-17 重庆大学 一种检测适用靶向p53的抗癌药的肿瘤患者的试剂盒
CN110538173A (zh) * 2019-08-20 2019-12-06 郑州大学第一附属医院 异硫氰酸酯类化合物在制备食管癌靶向药中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158111A1 (en) * 2011-12-20 2013-06-20 Georgetown University Compositions and Methods for Depleting Mutant p53

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158111A1 (en) * 2011-12-20 2013-06-20 Georgetown University Compositions and Methods for Depleting Mutant p53

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
XIANTAO WANG ET AL: "Selective depletion of mutant p53 by cancer chemopreventive isothiocyanates and its structure-activity relationships", 《J MED CHEM. AUTHOR MANUSCRIPT》 *
周霆等: "异硫氰酸酯类化合物的抗癌作用机制研究进展", 《解放军药学学报》 *
张雪等: "异硫氰酸苯乙酯通过上调ＲOS 激活p53诱导MCF-7 细胞凋亡机制的研究", 《中国临床药理学与治疗学》 *
魏付桥等: "异硫氰酸苯乙醋对结肠癌S从4 8 0 细胞PI 3 K / A ltc / m T O R信号通路的影响", 《实用心脑肺血管病杂志》 *

Also Published As

Publication number Publication date
CN107303291A (zh) 2017-10-31
WO2017181943A1 (zh) 2017-10-26

Similar Documents

Publication Publication Date Title
Tameire et al. Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy
Tirro et al. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells
Cheong et al. Casein kinase 1α–dependent feedback loop controls autophagy in RAS-driven cancers
Ma et al. Verteporfin induces apoptosis and eliminates cancer stem-like cells in uveal melanoma in the absence of light activation
Fukushiro-Lopes et al. Preclinical study of a Kv11. 1 potassium channel activator as antineoplastic approach for breast cancer
Duan et al. p53-regulated autophagy is controlled by glycolysis and determines cell fate
EP3397963A1 (en) Inhibition of p38 mapk for the treatment of cancer
JP6706635B2 (ja) がん治療のためのｅｇｆｒ−ｓｇｌｔ１相互作用の標的化
Abboud-Jarrous et al. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL
Zainal et al. Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance
CA2945635C (en) Pancreatic cancer therapy and diagnosis
CN109562093A (zh) 含peitc的药物组合物及其在癌症治疗中的应用
Li et al. F-box protein FBXW17-mediated proteasomal degradation of protein methyltransferase PRMT6 exaggerates CSE-induced lung epithelial inflammation and apoptosis
Tada et al. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma
US10206920B2 (en) Pharmaceutical composition for treating cancer and a method of using the same
Dong-Xiang et al. Cyclin-dependent kinase like 3 promotes triple-negative breast cancer progression via inhibiting the p53 signaling pathway.
US20200101070A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
KR20170071393A (ko) 방사선 저항성 진단용 조성물 및 이의 용도
Lai et al. Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways
de Lima ROle of the MITOchondrial fission protein DRP1 as a prognosis and predictive biomarker in the treatment of differentiated thyroid cancer (ROMITO-DRP1)
Yingying et al. Mitochondrial dysfunction induces radioresistance in colorectal cancer by activating [Ca2+] m-PDP1-PDH-histone acetylation retrograde signaling
Wilking-Busch The Potential Role and Therapeutic Significance of Sirtuins in Melanoma
Rabinovitch The Role of Adenosine Monophosphate-Activated Protein Kinase (AMPK) in Reactive Oxygen Species (ROS) Signalling and Cancer Cell
Paluncic Identification of Melanotransferrin (MTf), as a Novel Pro-Oncogenic Signalling Protein Involved in Melanoma Pathogenesis
Kessler Dissecting the dual roles of focal adhesion kinase (FAK) in thyroid cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination